Blurbs

Analysts Are Bullish on These Healthcare Stocks: CTI BioPharma (CTIC), Cormedix (CRMD)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CTI BioPharma (CTICResearch Report) and Cormedix (CRMDResearch Report) with bullish sentiments.

CTI BioPharma (CTIC)

JMP Securities analyst Reni Benjamin reiterated a Buy rating on CTI BioPharma today and set a price target of $9.00. The company’s shares closed last Monday at $7.06, close to its 52-week high of $7.80.

According to TipRanks.com, Benjamin ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.2% and a 37.0% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics.

CTI BioPharma has an analyst consensus of Strong Buy, with a price target consensus of $9.30, a 23.5% upside from current levels. In a report released yesterday, Brookline Capital Markets also maintained a Buy rating on the stock with a $12.00 price target.

See the top stocks recommended by analysts >>

Cormedix (CRMD)

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Cormedix, with a price target of $14.00. The company’s shares closed last Monday at $7.52.

According to TipRanks.com, Butler is ranked 0 out of 5 stars with an average return of -4.9% and a 41.4% success rate. Butler covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Aquestive Therapeutics, and ACADIA Pharmaceuticals.

Cormedix has an analyst consensus of Moderate Buy, with a price target consensus of $17.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CTIC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos